 |
 |
 |
 |
 |
 |
|
 Ophena™ |
| Fispemifene |
 Sobetirome |
| Asord™ |
 |
|
|
Our most advanced product candidate, Ophena™ (ospemifene), has completed Phase III clinical trials for the treatment of postmenopausal vaginal atrophy.
|
|
Terms of Use